High expression of microRNA‑500 is associated with poor prognosis in patients with acute myeloid leukemia receiving allogeneic hematopoietic stem cell transplantation

Zhang,Gaoqi; Shi,Jinlong; Yang,Xinrui; Zhang,Xinpei; Zhang,Lingxiu; Zhang,Jilei; Yang,Siyuan; Wang,Jing; Hu,Kai; Ke,Xiaoyan; Fu,Lin

doi:10.3892/ol.2019.10250

High expression of microRNA‑500 is associated with poor prognosis in patients with acute myeloid leukemia receiving allogeneic hematopoietic stem cell transplantation

Authors:
- Gaoqi Zhang
- Jinlong Shi
- Xinrui Yang
- Xinpei Zhang
- Lingxiu Zhang
- Jilei Zhang
- Siyuan Yang
- Jing Wang
- Kai Hu
- Xiaoyan Ke
- Lin Fu
View Affiliations

Affiliations: Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing 100191, P.R. China, Department of Biomedical Engineering, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China, Department of Hematology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China
Published online on: April 15, 2019 https://doi.org/10.3892/ol.2019.10250
Pages: 5815-5820

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA‑500 (miR‑500) is a potential prognostic biomarker in a number of different types of cancer, such as prostate cancer and hepatocellular carcinoma. This study aimed to explore the clinical implications of miR‑500 expression status in patients with acute myeloid leukemia (AML) that had received allogeneic hematopoietic stem cell transplantation (allo‑HSCT). miR‑500 expression status and clinical data were obtained from 74 patients with AML in the The Cancer Genome Atlas database receiving allo‑HSCT. Patients with low expression level of miR‑500 (miR‑500low) were significantly more likely to present with a French‑American‑British classification M2 subtype (P=0.003), and less likely to have the M5 subtype (P=0.040) compared with patients with high expression levels (miR‑500high). miR‑500low patients were associated with low‑risk AML (P=0.003) and core‑binding factor subunit b‑myosin heavy chain 11 translocation mutation (P=0.021). There was a significant difference in nucleophosmin 1 (P=0.009), NRAS proto‑oncogene GTPase/KRAS proto‑oncogene GTPase (P=0.047) and PHD finger protein 6 (P=0.040) expression levels between the two groups. miR‑500high patients had a decreased overall survival (OS) time compared with the low expression group (P=0.035). Multivariate analysis revealed that miR‑500 expression significantly affected OS time independent of other classical prognostic factors, such as age and common mutations. The analysis of survival curves further substantiated this result. The results obtained in the current study suggested that miR‑500 may be a suitable prognostic marker for patients with AML receiving allo‑HSCT.

View Figures

View References

1	Cazzola M, Della Porta MG, Travaglino E and Malcovati L: Classification and prognostic evaluation of myelodysplastic syndromes. Semin Oncol. 38:627–634. 2011. View Article : Google Scholar : PubMed/NCBI
2	Wang YX, Zhang TJ, Yang DQ, Yao DM, Yang L, Zhou JD, Deng ZQ, Ma JC, Guo H, Wen XM, et al: Reduced miR-215 expression predicts poor prognosis in patients with acute myeloid leukemia. Jpn J Clin Oncol. 46:350–356. 2016. View Article : Google Scholar : PubMed/NCBI
3	Döhner H, Weisdorf DJ and Bloomfield CD: Acute myeloid leukemia. N Engl J Med. 373:1136–1152. 2015. View Article : Google Scholar : PubMed/NCBI
4	Marcucci G, Haferlach T and Dohner H: Molecular genetics of adult acute myeloid leukemia: Prognostic and therapeutic implications. J Clin Oncol. 29:475–486. 2011. View Article : Google Scholar : PubMed/NCBI
5	Agirre X, Martínez-Climent JÁ, Odero MD and Prósper F: Epigenetic regulation of miRNA genes in acute leukemia. Leukemia. 26:395–403. 2012. View Article : Google Scholar : PubMed/NCBI
6	Zhang R and Su B: Small but influential: The role of microRNAs on gene regulatory network and 3′UTR evolution. J Genet Genomics. 36:1–6. 2009. View Article : Google Scholar : PubMed/NCBI
7	Palma CA, Tonna EJ, Ma DF and Lutherborrow MA: MicroRNA control of myelopoiesis and the differentiation block in acute myeloid leukaemia. J Cell Mol Med. 16:978–987. 2012. View Article : Google Scholar : PubMed/NCBI
8	Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 99:15524–15529. 2002. View Article : Google Scholar : PubMed/NCBI
9	Yamamoto Y, Kosaka N, Tanaka M, Koizumi F, Kanai Y, Mizutani T, Murakami Y, Kuroda M, Miyajima A, Kato T and Ochiya T: MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers. 14:529–538. 2009. View Article : Google Scholar : PubMed/NCBI
10	Cai B, Chen W, Pan Y, Chen H, Zhang Y, Weng Z and Li Y: Inhibition of microRNA-500 has anti-cancer effect through its conditional downstream target of TFPI in human prostate cancer. Prostate. 77:1057–1065. 2017. View Article : Google Scholar : PubMed/NCBI
11	Zhang L, Ding Y, Yuan Z, Liu J, Sun J, Lei F, Wu S, Li S and Zhang D: MicroRNA-500 sustains nuclear factor-κB activation and induces gastric cancer cell proliferation and resistance to apoptosis. Oncotarget. 6:2483–2495. 2015.PubMed/NCBI
12	Cancer Genome Atlas Research Network, ; Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K, Triche TJ Jr, Laird PW, et al: Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 368:2059–2074. 2013. View Article : Google Scholar : PubMed/NCBI
13	Mrózek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, Metzeler KH, Schwind S, Wu YZ, Kohlschmidt J, et al: Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 30:4515–4523. 2012. View Article : Google Scholar : PubMed/NCBI
14	Xue E, Tresoldi C, Sala E, Crippa A, Mazzi B, Greco R, Messina C, Carrabba MG, Lupo Stanghellini MT, Marktel S, et al: Longitudinal qPCR monitoring of nucleophosmin 1 mutations after allogeneic hematopoietic stem cell transplantation to predict AML relapse. Bone Marrow Transplant. 51:466–469. 2016. View Article : Google Scholar : PubMed/NCBI
15	Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, Battiwalla M, Bornhauser M, Cahn JY, Camitta B, et al: Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 122:3005–3014. 2016. View Article : Google Scholar : PubMed/NCBI
16	Tang S, Shen H, Mao X, Dai H, Zhu X, Xue S, Ding Z, Lu J, Wu D and Tang X: FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation. Int J Hematol. 106:552–561. 2017. View Article : Google Scholar : PubMed/NCBI
17	Chan NP, Wong WS, Ng MH, Tsang KS, Lau TT, Leung Y, Chik KW, Shing MM and Li CK: Childhood acute myeloid leukemia with CBFbeta-MYH11 rearrangement: Study of incidence, morphology, cytogenetics, and clinical outcomes of Chinese in Hong Kong. Am J Hematol. 76:300–303. 2004. View Article : Google Scholar : PubMed/NCBI
18	Van Vlierberghe P, Patel J, Abdel-Wahab O, Lobry C, Hedvat CV, Balbin M, Nicolas C, Payer AR, Fernandez HF, Tallman MS, et al: PHF6 mutations in adult acute myeloid leukemia. Leukemia. 25:130–134. 2011. View Article : Google Scholar : PubMed/NCBI